https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Meta-analyses of newer antiepileptic drugs as adjunct for treatment of focal epilepsy in children https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33760 50% seizure reduction, and a trend of better seizure freedom. Their tolerability would also be considered acceptable with the observed low withdrawal rate. However, the relative lack of well-conducted RCTs evaluating their effectiveness against other active AED treatment in children would not facilitate evidence-based practice. This highlights the knowledge gap and the need for more well-conducted RCTs against active treatments to ascertain the long term effectiveness and the role of newer AEDs in managing epilepsy in children.]]> Tue 03 Sep 2019 17:57:39 AEST ]]> Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: a meta-analysis of randomized placebo-controlled trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19475 Sat 24 Mar 2018 08:02:21 AEDT ]]> Reliability and validity of QOLIE-10 in measuring health-related quality of life (HRQoL) in Chinese epilepsy patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20987 QOLIE-10, whereas there were fewer predictors for HRQoLEQ-5D or HRQoLQWB-SA. Conclusions: QOLIE-10 appeared to be a reliable and sensitive instrument to assess the HRQoL for epilepsy patients. According to the MLR analyses, numbers of AEDs, refractory epilepsy, comorbidity depression, and cognitive function were demonstrated to be predictors of HRQoL dependent on different tools. Comparisons between the tools suggested epilepsy-specific instrument was more competent to discriminate HRQoL based on condition variables. However, a longitudinal study is still needed to examine the responsiveness of Chinese QOLIE-10.]]> Sat 24 Mar 2018 07:50:41 AEDT ]]> Burden of epilepsy: a prevalence-based cost of illness study of direct, indirect and intangible costs for epilepsy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23416 Sat 24 Mar 2018 07:13:53 AEDT ]]>